TrialCompass™ TCL
Back to results
Phase 1RecruitingPriority 2 · High priorityNCT07195916

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is comparing different first-line treatment approaches for people newly diagnosed with anaplastic large cell lymphoma (ALCL). Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 8 US locations across multiple states.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

INCA036873 (DRUG): Intravenously (IV)

Drugs / treatments
INCA036873
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

NCT07195916

Phase: Phase 1 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 1 trial is comparing different first-line treatment approaches for people newly diagnosed with anaplastic large cell lymphoma (ALCL). Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 8 US locations across multiple states.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

INCA036873 (DRUG): Intravenously (IV)

Drugs / treatments: INCA036873

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 280 patients

Primary endpoint: Part 1A : Occurrence of Dose Limiting Toxicities (DLTs); Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Ages: 18 Years to —

Start date: 2026-01-08 | Est. completion: 2028-08-18

Locations

8 US sites · 22 total

California, Michigan, Nebraska, New York, Tennessee, Texas

Contact

Incyte Corporation Call Center (US) | medinfo@incyte.com | 1.855.463.3463

Sponsor: Incyte Corporation (INDUSTRY)

Tags

ALCL · CTCL · Newly diagnosed · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07195916

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.